已上市HIV整合酶抑制剂及其合成介绍
|
摘要
整合酶是艾滋病毒(HIV)复制过程中的四个关键酶之一。目前已作为药物上市的艾滋病毒整合酶抑制剂一共有四种,分别是拉替拉韦、多替拉韦、埃替格韦和bictegravir,分别介绍了这四种整合酶抑制剂的情况及其化工企业可行的制备方法。
Integrase is one of the four key enzymes in the HIV replication process. There are four HIV integrase inhibitors currently on the market. These are raltegravir, dolutegravir, elvitegravir and bictegravir. This article introduces the four integrase inhibitors and their feasible preparation methods in chemical industry.
Integrase is one of the four key enzymes in the HIV replication process. There are four HIV integrase inhibitors currently on the market. These are raltegravir, dolutegravir, elvitegravir and bictegravir. This article introduces the four integrase inhibitors and their feasible preparation methods in chemical industry.
引文
[1]梁贵柏.新药研发的故事[M].上海:上海三联书店,2014.
[2]朱梅,张国宁,白晓光,等.HIV-1整合酶抑制剂研究进展[J].中国医药生物技术,2017(12):342-349.
[3]陈同辛,郝铁群.艾滋病发病机制研究进展[J].实用儿科临床杂志,2004(19):531-534.
[4]罗丽娟,黄璐,张玉芹.HIV整合酶抑制剂药物研究与应用[J].中国新药与临床杂志,2014(33):481-484.
[5]闫世凤,赵桂森,孙健,等.HIV-1整合酶抑制剂的研究进展[J].中国抗生素杂志,2007(32):577-581.
[6]百威,田敏卿,马亚平,等.HIV-1整合酶抑制剂研究进展[J].中国艾滋病性病,2006(12):81-84.
[7]郭涤亮,刘冠男,周宇,等.HIV整合酶抑制剂的研究进展[J].有机化学,2010(30):477-485.
[8]Daria J.Hazuda,Peter Felock,Marc Witmer,et al.Miller inhibitors of strand transfer that prevent integration and inhibit HIV-1replication in cells[J].Science,2000(287):646-650.
[9]张楠,张惠斌,黄山.抗HIV整合酶抑制剂研究进展[J].药物生物技术,2009(16):269-274.
[10]FDA notification.Raltegravir indication extended for treatment-naive patients[J].AIDS Alert,2009(24):93.
[11]宋贤,杨维林.拉替拉韦治疗HIV感染研究进展[J].传染病信息,2013(26):251-253.
[12]Kevin M.Belyk,Henry G.Morrison,Amar J.Mahajan,et al.Kumke,Hsien-Hsin Tung,Lawrence Wai,Vanessa Pruzinsky.Potassium salt of an HIV integrase inhibitor[P].United States,US:7754731.
[13]张道旭,李超.拉替拉韦的合成工艺改进[J].国际药学研究杂志,2017(44):595-599.
[14]林永强,刘新泳,王淑华.HIV-1整合酶抑制剂的研究进展[J].中国医药工业杂志,2006(37):279-285.
[15]李艳玲,刘洪森,王彩霞,等.抗艾滋病新药---杜鲁特韦[J].新药介绍,2015(34):1064-1066.
[16]Srimurugan Sankarewaran,Madhavarao Mannam,Veerababu Chakka,et al.Identification and control of critical process impurities:an improved process for the preparation of dolutegravir sodium[J].Organic Process Research&Development,2016,20(8):1461-1468.
[17]黄举,刘宏民,刘明亮.第一个喹诺酮类抗HIV药物埃替格韦[J].国外医药抗生素分册,2013(34):157-160.
[18]马帅,赵俊,杜宏伟,等.埃替拉韦的合成[J].中国医药工业杂志,2014(45):5-8.
[19]Scott E.Lazerwith,Haolun Jin,Hyung-Jung Pyun.Polycyclic-carbamoylpyridone compounds and their pharmaceutical use[P].US:20140221355.
[20]李方琼,丁倩,詹金彪.HIV-1整合酶及其抑制剂的研究进展[J].中国生物工程杂志,2008(28):80-86.
[2]朱梅,张国宁,白晓光,等.HIV-1整合酶抑制剂研究进展[J].中国医药生物技术,2017(12):342-349.
[3]陈同辛,郝铁群.艾滋病发病机制研究进展[J].实用儿科临床杂志,2004(19):531-534.
[4]罗丽娟,黄璐,张玉芹.HIV整合酶抑制剂药物研究与应用[J].中国新药与临床杂志,2014(33):481-484.
[5]闫世凤,赵桂森,孙健,等.HIV-1整合酶抑制剂的研究进展[J].中国抗生素杂志,2007(32):577-581.
[6]百威,田敏卿,马亚平,等.HIV-1整合酶抑制剂研究进展[J].中国艾滋病性病,2006(12):81-84.
[7]郭涤亮,刘冠男,周宇,等.HIV整合酶抑制剂的研究进展[J].有机化学,2010(30):477-485.
[8]Daria J.Hazuda,Peter Felock,Marc Witmer,et al.Miller inhibitors of strand transfer that prevent integration and inhibit HIV-1replication in cells[J].Science,2000(287):646-650.
[9]张楠,张惠斌,黄山.抗HIV整合酶抑制剂研究进展[J].药物生物技术,2009(16):269-274.
[10]FDA notification.Raltegravir indication extended for treatment-naive patients[J].AIDS Alert,2009(24):93.
[11]宋贤,杨维林.拉替拉韦治疗HIV感染研究进展[J].传染病信息,2013(26):251-253.
[12]Kevin M.Belyk,Henry G.Morrison,Amar J.Mahajan,et al.Kumke,Hsien-Hsin Tung,Lawrence Wai,Vanessa Pruzinsky.Potassium salt of an HIV integrase inhibitor[P].United States,US:7754731.
[13]张道旭,李超.拉替拉韦的合成工艺改进[J].国际药学研究杂志,2017(44):595-599.
[14]林永强,刘新泳,王淑华.HIV-1整合酶抑制剂的研究进展[J].中国医药工业杂志,2006(37):279-285.
[15]李艳玲,刘洪森,王彩霞,等.抗艾滋病新药---杜鲁特韦[J].新药介绍,2015(34):1064-1066.
[16]Srimurugan Sankarewaran,Madhavarao Mannam,Veerababu Chakka,et al.Identification and control of critical process impurities:an improved process for the preparation of dolutegravir sodium[J].Organic Process Research&Development,2016,20(8):1461-1468.
[17]黄举,刘宏民,刘明亮.第一个喹诺酮类抗HIV药物埃替格韦[J].国外医药抗生素分册,2013(34):157-160.
[18]马帅,赵俊,杜宏伟,等.埃替拉韦的合成[J].中国医药工业杂志,2014(45):5-8.
[19]Scott E.Lazerwith,Haolun Jin,Hyung-Jung Pyun.Polycyclic-carbamoylpyridone compounds and their pharmaceutical use[P].US:20140221355.
[20]李方琼,丁倩,詹金彪.HIV-1整合酶及其抑制剂的研究进展[J].中国生物工程杂志,2008(28):80-86.